The Pandemic’s Impact On Health Care Design: Smaller, Flexible Spaces With Great Adaptability

The pandemic rocked U.S. health care facilities in 2020, leaving them with falling revenue from moneymaking surgeries and ordinary care as physicians and nurses shifted their attention toward patients infected with the coronavirus.

But the real change will come three to four years from now, when the impact of new designs implemented on existing and new healthcare facilities are deployed based on what architects and physicians have learned over the past nine months.

“Health care clients are already shifting their focus and asking for smaller footprints and more space flexibility along with additional isolated, negative air pressure rooms,” said Architect and EYP principal Miranda Morgan, while speaking at Bisnow‘s ‘The Future of DFW Healthcare’ webinar. “The smaller footprints are just more efficient and lean. We are still providing everything that is needed, and we are still doing big huge patient towers. But instead of big luxury, patient rooms, clients are asking us to be closer to code and to get what you need in that space and provide the patient with a good experience, but don’t go overboard.”

A large focus of future design will be on keeping healthy and sick patients separate rather than feeding everyone through the same access points and maneuvering the same hallways. Luxurious common areas have lost some favor as health care systems shift toward making sure more rooms are available to isolate emergency care and hospital inpatients while also better managing various points of access to segregate healthy and sick populations on-site.

“We are examining the way patients flow through the facilities,” said Dwain ThieleUT Southwestern Medical Centersenior associate dean. “Some of the most challenging are imaging facilities or places that previously did not have a large amount of space, hallways or waiting rooms. It is something we will be looking at in the future.”

“What we have seen through the pandemic from a needs standpoint is more access points for people to be seen and to have access whether through telehealth or smaller, faster clinics where people can get in and out,” Transwestern National Managing Director of Healthcare John Huff said. “I guess we realize we don’t all want to sit in a huge long waiting room for an hour.”

In the future, waiting rooms very well could be a thing of the past, with that square footage allocated to more isolated treatment rooms, health care experts said.

“Other trends here to stay include the ongoing push for more outpatient care centers and ambulatory facilities that can take care of non-life-threatening illnesses while hospitals are hit with pandemics,” Huff said.

“Technology also will play a significant role in reshaping the future of health care, with telemedicine, or remote health care visits, allowing hospitals to keep healthier patients away from pandemic-stricken areas,Methodist Health System Chief Operating Officer Pamela Stoyanoffsaid. “I would say prior to COVID, we probably saw about 1% of visits in the outpatient setting with telehealth. In April and May, when we saw the first surge, we were probably up to 80% to 90% of our visits. When some of the restrictions lifted, telehealth usage dropped back down to 15%, but it’s expected to have a place in the future of health care services. It is now a massive part of what we do, and it is here to stay.”

 

Source: Bisnow

Medical Office Building Developers See Opportunities And Expect Project Growth In 2021

Although medical office buildings (MOBs) are once again showing their strength as an investment and ownership product during the COVID-19 pandemic, some professionals involved in the sector have expressed concern that there could be a slowdown in the development of such facilities in the next couple of years.

Although such a concern could indeed prove to be true, professionals with some of the MOB sector’s largest and best-known development firms, as well as full-service healthcare real estate HRE) firms that provide development services, recently expressed that they are remaining as busy as ever, and should be for at least the next year or longer.

HREI™ Editorial Advisory Board members say the number of requests for proposals (RFPs) and the level of development activity during the COVID-19 pandemic have come as a pleasant surprise, and they say they expect 2021 to be another strong year.

 

Source: HREi

Bio Boom: Dallas-Fort Worth Is Emerging As A Hub For Biotech And Life Sciences

Dallas-Fort Worth leads the nation in population and job growth, and the region was No.1 in both categories for 2019 and for the entire 2010 decade, for good reason.

Considered a premier location in the U.S. for headquarters, manufacturers, and logistics, DFW is home to an enviable roster of companies across major sectors like aerospace, automotive, data, energy, engineering, insurance, finance, food and beverage, retail, semiconductors, telecommunications, and transportation.

Eight Fortune 500 companies have decided to move headquarters to DFW since 2004. The most recent is Charles Schwab, whose move to Westlake from San Francisco will take effect Jan. 1, 2021.

DFW is also out front with new and emerging sectors. Artificial intelligence, augmented reality, autonomous vehicles, big data, cybersecurity, and distributed ledger technology companies and jobs are here, and growing. DFW has it all. Almost.

You have not seen Dallas at or near the top of any list of “best cities” or “best places for” when the ranking is based on life sciences or biotechnology.  Chances are the City is not on the list at all. Boston, San Francisco, San Diego, Washington D.C., Raleigh-Durham, New York, New Jersey, and a few others share that spotlight.

More than most sectors, biotech companies cluster when choosing where to build facilities, invest and create jobs, even if costs are higher. Boston, San Francisco, and the others offer the established and branded aggregate of great research universities, existing and significant biotech and life science companies, a big talent pool, lab space, patent generation, and funding from venture capital firms or the National Institutes of Health.

Yet in recent years, the Dallas Regional Chamber has led bids that advanced DFW as a finalist for new biotechnology manufacturing facilities by Genentech, Novartis, and a few others. DFW was in the game on the strength of overall attributes as a great place to do business and a few stellar centers of biotech excellence like Alcon in Fort Worth and UT Southwestern Medical Center in Dallas, the only academic medical center in the world to serve as home to six Nobel Laureates.

With a funding level of about $470 million annually, UT Southwestern Medical Center is a shining star. UT Southwestern conducts research and launches companies across a variety of fields including cancer, heart disease, and neuroscience; as well as training 3,600 medical professionals each year. Yet DFW was not selected. The biotech ecosystem was not as deep or evident compared to the winning locations. Now that’s changing quickly, for the better.

On Sept. 22, 2020,  biotech industry leader BioLabs announced that it is locating its first central U.S. location in  Dallas. BioLabs provides lab space and wrap-around services to incubate and accelerate biotech. BioLabs will operate in a 37,000 square-foot flexible life science coworking facility at Pegasus Park, developed by J. Small Investments, partnering with Lyda Hill Philanthropies. Pegasus Park is just north of downtown Dallas and is within walking distance of UT Southwestern Medical Center, a collaborator on the Park. BioLabs’ other locations are in hotspots like Boston, New York, San Diego, and Raleigh-Durham; places where, for years, Dallas entrepreneurs, scientists, and researchers sometimes had to go to launch their enterprises.

Companies like Alcon, Astra Zeneca, Peloton Therapeutics, Reata Pharmaceuticals, and Taysha Gene Therapies are in Dallas-Fort Worth, working on eye care, hyperkalemia, cancer, kidney disease, and diseases of the central nervous system. Other science in the region is focused on HIV, muscular dystrophy, brain research, and more. The University of North Texas Health Science Center in Fort Worth is conducting research in forensic genetics and Alzheimer’s. Texas A&M’s College of Dentistry in Dallas is nationally recognized for oral health and craniofacial research. As the region grows in population and diversity, researchers will be increasingly attracted here for clinical trials.

There are more than 60 companies and 27,000 jobs in biotechnology and life sciences in DFW. McKesson, a Fortune 10 company and the nation’s largest pharmaceutical distributor, is now headquartered in Irving, for good reason. Dallas Fort Worth International Airport boasts a new 37,000-square-foot cold chain storage facility. It allows the refrigerated storage and rapid delivery to and from the region of temperature and time-sensitive pharmaceuticals and therapies.

There is a lot of runway in the biotechnology sector in DFW, and the assets and reputation are building in a positive direction. Objective third parties are taking note. In an October 2020 life science cluster report by CBRE, DFW was ranked 6th on a list of top ten emerging life science clusters in the U.S. Biotechnology is alive and growing in DFW.

 

Source: Dallas Innovates